Among the highlights in clinical hematology, during the 8th International Oncoclinical Symposium are the main advances related to CAR-T cell therapy. “It is an extremely important and current issue that is starting to be discussed in our country”, says Carla Boquimpani, hematology leader at Grupo Oncoclínicas and coordinator of the symposium’s hematology program.
To date, hematologic malignancies are the main applications of CAR-T cell therapy, having been successful in cases of acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. In Brazil, however, the technique is not yet available outside of clinical studies. “The conditions are still being developed so that it is possible to carry out therapy with CAR-T Cell in Brazil”, explains the coordinator. One of the main challenges is in relation to the manufacture of the modified cells, since each treatment uses the patient’s own cells.
Of a multidisciplinary nature, the hematology session also had the participation of pathologist Carlos Alberto Guaxupé, from the Roberto Alvarenga Institute, in Minas Gerais. At the table on Hodgkin’s lymphoma, he showed a slide view of the tumor under a microscope. “It was very enlightening and very interesting”, says Carla.